Summary

Eligibility
for people ages up to 99 years (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.

Official Title

N2004-05: Neuroblastoma Biology Study

Details

The purposes of this study are:

To establish a storage place or bank of samples of blood, bone marrow, and/or tumor, and molecular components isolated from these samples from children with neuroblastoma. The stored specimens will be shared with laboratory researchers studying high risk neuroblastoma.

To collect clinical data (such as treatments received, date of diagnosis, tumor stage, etc) and radiology scans to provide this information as needed for the laboratory studies to be done on the specimens.

To obtain neuroblastoma tumor cells from tumor tissue, bone marrow, and/or blood to use to start cell lines, or tumor cells that will keep growing in the laboratory. These cell lines will be shared with laboratory researchers studying high risk neuroblastoma.

Keywords

Neuroblastoma

Eligibility

You can join if…

Open to people ages up to 99 years

  • Patients must be greater than or 31 days of age.
  • Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
  • All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
  • Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.

You CAN'T join if...

  • There are no exclusion criteria on this study.

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center accepting new patients
    San Francisco California 94115 United States
  • Lucille Salter Packer Children's Hospital, Stanford University completed
    Palo Alto California 94305 United States
  • Children's Hospital Los Angeles accepting new patients
    Los Angeles California 90027-0700 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
New Approaches to Neuroblastoma Therapy Consortium
ID
NCT01587300
Study Type
Observational
Participants
Expecting 1000 study participants
Last Updated